USPTO Patent Grant: Cancer Treatment Compositions

The United States Patent and Trademark Office (USPTO) has issued patent US12582690B2, granting exclusive rights to the Korea Institute of Science and Technology for novel compositions designed to prevent or treat cancer. These compositions utilize extracts from the plant Rubus longisepalus var. tozawai (Nakai) T.B.Lee, or fractions thereof, as active ingredients. The patent highlights the extract's efficacy against various cancers, specifically mentioning diffuse-type gastric cancer, suggesting potential for developing new therapeutic agents.

This patent grant represents a new intellectual property right for a specific therapeutic composition. While it does not impose direct compliance obligations on other entities, it establishes exclusive rights for the assignee. Companies operating in the oncology space, particularly those researching or developing plant-based therapeutics, should be aware of this patent to avoid potential infringement. The patent's abstract and CPC classifications (including A61P 35/00 for Antineoplastic and antimetabolite drugs) indicate the specific area of innovation.